|
|
Volume : V, Issue : III, May - 2021
CONCURRENT PACLITAXEL AND RADIATION THERAPY IN CISPLATIN CONTRAINDICATED LOCALLY ADVANCED HEAD AND NECK CANCER - A PROSPECTIVE STUDY
Abstract :
Concurrent chemoradiation with Cisplatin is the standard of care in locally advanced head and neck cancer. The present study was done with Paclitaxel, a potent radiosensitiser in Cisplatin contraindicated patients. Fifty patients of non-metastatic locally advanced squamous cell carcinoma in whom cisplatin was contraindicated were divided into two arms. Arm 1 received weekly Paclitaxel 40mg/m2 along with External Beam Radiotherapy. Arm 2 received Ext RT only. In the combined arm 60% showed complete response (CR) whereas 20% had partial response (PR) with a total response of 80%. In the RT only arm 40% had CR and 20% had PR with total response of 60%. Grade II/III mucositis the major toxicity was seen in 88% cases in combined against 36% in the single arm. Concurrent Paclitaxel + RT showed excellent results with increased toxicity.
Keywords :
Cite This Article:
CONCURRENT PACLITAXEL AND RADIATION THERAPY IN CISPLATIN CONTRAINDICATED LOCALLY ADVANCED HEAD AND NECK CANCER - A PROSPECTIVE STUDY, DR RAJAT BANDYOPADHYAY, DR SUPARNA BANERJEE, INTERNATIONAL JOURNAL OF ADVANCED MEDICINE : Volume-5 | Issue-3 | May-2021
[ Download PDF ] [ Number of Downloads : 1196 ]
Disclaimer: Articles on International Journal of Advances In Surgery have been previewed and authenticated by the Authors before sending the publication for print.
The Journal, Editor and the Board of Members are not entitled or liable to either justify or responsible for inaccurate and misleading data if any.
It is the sole responsibility of the Author concerned. If any queries or infringement occurs
Copyrights © 2023: International Journal of Advances In Surgery (IJAS)